Fresh news on culture and lifestyle in New Zealand
Provided by AGP
Evergen Named “Best Overall MedTech Company” in 10th Annual MedTech Breakthrough Awards Program
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market, today announced that Evergen, a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, has been selected as winner of the “Best Overall MedTech Company” award in the 10th annual MedTech Breakthrough Awards program.
Evergen’s agile, patient-first Contract Development and Manufacturing Organization (CDMO) partnership model and clinical expertise allow it to deliver the optimum biomaterial in the ideal form for each procedure, with comprehensive, end-to-end services. Evergen partners with Original Equipment Manufacturers (OEMs) to design, develop, and manufacture customized biomaterial solutions for regenerative medicine that promote healing, accelerate recovery and help prevent complications to enhance patient lives.
Evergen focuses on specialized clinical areas, including plastic and reconstructive surgery, sports medicine and orthopedics, neuro/spine, and cardiac. By combining deep clinical and advanced biomaterials expertise, Evergen first collaborates with OEMs to understand patients' unique needs, clinical applications, and gaps in existing treatment options. The company then leverages its extensive portfolio of allograft and xenograft biomaterials to develop the best biomaterial in the ideal form for each procedure.
Complemented by a robust ISO 13485–compliant multi–site infrastructure, a rigorous quality management program and comprehensive capabilities, the company has the flexibility to tailor and scale end-to-end services for customers, from startups to global medical device leaders. With Evergen, customers can build scalable solutions by optimizing processes and advancing manufacturing capabilities.
“Our ability to work with multi-source biomaterials at scale while ensuring quality, reliability, and supply assurance is why we stand out and why OEMs can rely on us. Our customers consistently cite our team and collaborative culture as a defining strength, enabling faster innovation and more effective problem-solving,” said Olivier Visa, CEO of Evergen. “We’re grateful to MedTech Breakthrough for this acknowledgment. At our core, it is passion, agility, and an unwavering focus on improving patient outcomes that guide how we solve challenges for our partners and help them meet ambitious goals.”
Now celebrating its 10th anniversary, the MedTech Breakthrough Awards program has spent a decade recognizing the companies driving meaningful progress and improving patient care across the global health and medical technology industry. The program spans a wide range of categories – including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices and beyond – honoring the innovations reshaping
how care is delivered worldwide.
This year's program drew a record-breaking number of nominations from leading companies and startups across more than 20 countries, reflecting the growing global impact and momentum of the digital healthcare industry.
“Evergen is redefining what it means to be a CDMO in regenerative medicine by leading with the patient. Traditional innovation approaches usually begin with biomaterials, Evergen goes beyond by first considering unmet clinical and patient needs. This makes turning concepts into practical solutions for regenerative medicine that meet functional, mechanical and regulatory standards for clinical use incredibly complex,” said Steve Johansson, managing director, MedTech Breakthrough. “Through ongoing investment in talent, operational excellence, and next-generation biomaterials, Evergen is shaping the future of regenerative medicine as a trusted, agile, and innovative partner.”
Additionally, Evergen participates in the Medical Device Discovery Appraisal Program (MDDAP), a voluntary program that helps medical device manufacturers better understand, measure, and improve their capabilities to deliver high-quality products.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
About Evergen
Evergen is a leading Contract Development and Manufacturing Organization (CDMO) pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. Using our extensive portfolio of biological materials, we focus on specialized clinical segments, including plastic and reconstructive surgery, sports medicine and orthopedics, cardiac, and neurosurgery. Headquartered in Alachua, Florida, Evergen has facilities in the United States, Europe and New Zealand. For more information, visit www.evergenbio.com.
Media Contact Steve Johansson steve@medtechbreakthrough.com 213.255.3658
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
